199 related articles for article (PubMed ID: 33804433)
1. Identification of Novel Transcriptome Signature as a Potential Prognostic Biomarker for Anti-Angiogenic Therapy in Glioblastoma Multiforme.
Zheng S; Tao W
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33804433
[TBL] [Abstract][Full Text] [Related]
2. Identification of a cullin5-RING E3 ligase transcriptome signature in glioblastoma multiforme.
Zheng S; Li Z
Aging (Albany NY); 2020 Sep; 12(17):17380-17392. PubMed ID: 32931454
[TBL] [Abstract][Full Text] [Related]
3. Identification of a multidimensional transcriptome signature for survival prediction of postoperative glioblastoma multiforme patients.
Gao WZ; Guo LM; Xu TQ; Yin YH; Jia F
J Transl Med; 2018 Dec; 16(1):368. PubMed ID: 30572911
[TBL] [Abstract][Full Text] [Related]
4. Integrating cullin2-RING E3 ligase as a potential biomarker for glioblastoma multiforme prognosis and radiosensitivity profiling.
Zheng S; Wu Y; Li Z
Radiother Oncol; 2021 Jan; 154():36-44. PubMed ID: 32918970
[TBL] [Abstract][Full Text] [Related]
5. Establishment and External Validation of a Hypoxia-Derived Gene Signature for Robustly Predicting Prognosis and Therapeutic Responses in Glioblastoma Multiforme.
Wang K; Lu Y; Liu Z; Diao M; Yang L
Biomed Res Int; 2022; 2022():7858477. PubMed ID: 35155681
[TBL] [Abstract][Full Text] [Related]
6. A Five-lncRNAs Signature-Derived Risk Score Based on TCGA and CGGA for Glioblastoma: Potential Prospects for Treatment Evaluation and Prognostic Prediction.
Niu X; Sun J; Meng L; Fang T; Zhang T; Jiang J; Li H
Front Oncol; 2020; 10():590352. PubMed ID: 33392085
[TBL] [Abstract][Full Text] [Related]
7. A novel Foxp3-related immune prognostic signature for glioblastoma multiforme based on immunogenomic profiling.
Guo XY; Zhang GH; Wang ZN; Duan H; Xie T; Liang L; Cui R; Hu HR; Wu Y; Dong JJ; He ZQ; Mou YG
Aging (Albany NY); 2021 Jan; 13(3):3501-3517. PubMed ID: 33429364
[TBL] [Abstract][Full Text] [Related]
8. Molecular and Clinicopathological Characterization of a Prognostic Immune Gene Signature Associated With MGMT Methylation in Glioblastoma.
Zhao L; Zhang J; Xuan S; Liu Z; Wang Y; Zhao P
Front Cell Dev Biol; 2021; 9():600506. PubMed ID: 33614641
[No Abstract] [Full Text] [Related]
9. A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma.
Chai R; Zhang K; Wang K; Li G; Huang R; Zhao Z; Liu Y; Chen J
J Cancer Res Clin Oncol; 2018 Mar; 144(3):439-447. PubMed ID: 29299749
[TBL] [Abstract][Full Text] [Related]
10. A 35-gene signature discriminates between rapidly- and slowly-progressing glioblastoma multiforme and predicts survival in known subtypes of the cancer.
Fatai AA; Gamieldien J
BMC Cancer; 2018 Apr; 18(1):377. PubMed ID: 29614978
[TBL] [Abstract][Full Text] [Related]
11. A RNA sequencing-based six-gene signature for survival prediction in patients with glioblastoma.
Zuo S; Zhang X; Wang L
Sci Rep; 2019 Feb; 9(1):2615. PubMed ID: 30796273
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive analysis of the angiogenesis-related genes in glioblastoma multiforme vs. brain lower grade glioma.
Biterge-Sut B
Arq Neuropsiquiatr; 2020 Jan; 78(1):34-38. PubMed ID: 32074192
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Han J; Puri RK
J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
[TBL] [Abstract][Full Text] [Related]
14. Identification of potential biomarkers related to glioma survival by gene expression profile analysis.
Hsu JB; Chang TH; Lee GA; Lee TY; Chen CY
BMC Med Genomics; 2019 Mar; 11(Suppl 7):34. PubMed ID: 30894197
[TBL] [Abstract][Full Text] [Related]
15. Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses.
Liu YQ; Wu F; Li JJ; Li YF; Liu X; Wang Z; Chai RC
Front Oncol; 2019; 9():1433. PubMed ID: 31921684
[No Abstract] [Full Text] [Related]
16. A 63 signature genes prediction system is effective for glioblastoma prognosis.
Zhang Y; Xu J; Zhu X
Int J Mol Med; 2018 Apr; 41(4):2070-2078. PubMed ID: 29393370
[TBL] [Abstract][Full Text] [Related]
17. Integrated profiling identifies caveolae-associated protein 1 as a prognostic biomarker of malignancy in glioblastoma patients.
Guo Q; Guan GF; Cheng W; Zou CY; Zhu C; Cheng P; Wu AH
CNS Neurosci Ther; 2019 Mar; 25(3):343-354. PubMed ID: 30311408
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastoma.
Pangeni RP; Zhang Z; Alvarez AA; Wan X; Sastry N; Lu S; Shi T; Huang T; Lei CX; James CD; Kessler JA; Brennan CW; Nakano I; Lu X; Hu B; Zhang W; Cheng SY
Epigenetics; 2018; 13(4):432-448. PubMed ID: 29927689
[TBL] [Abstract][Full Text] [Related]
19. ADAMTSL4, a Secreted Glycoprotein, Is a Novel Immune-Related Biomarker for Primary Glioblastoma Multiforme.
Zhao Z; Zhang KN; Chai RC; Wang KY; Huang RY; Li GZ; Wang YZ; Chen J; Jiang T
Dis Markers; 2019; 2019():1802620. PubMed ID: 30728876
[TBL] [Abstract][Full Text] [Related]
20. T cell immune regulator 1 is a prognostic marker associated with immune infiltration in glioblastoma multiforme.
Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
Oncol Lett; 2021 Apr; 21(4):252. PubMed ID: 33664816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
